FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Feb 2023 16:27:22 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference

08 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

17 Jan 2023 22:15:16 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

17 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

04 Jan 2023 06:02:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces CEO Transition

04 Jan 2023 06:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2022 16:20:59 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

01 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Nov 2022 17:33:20 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

08 Nov 2022 06:17:58 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

07 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

02 Nov 2022 06:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

01 Nov 2022 16:29:02 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

12 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Oct 2022 16:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Sep 2022 16:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences

06 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit

16 Aug 2022 06:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

15 Aug 2022 20:28:02 By Nasdaq GlobeNewswire